{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:24Z","timestamp":1792887804026,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171398"],"award-info":[{"award-number":["82171398"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00415-024-12567-y","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T20:19:26Z","timestamp":1721420366000},"page":"6004-6014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-term impact of nusinersen on motor and electrophysiological outcomes in adolescent and adult spinal muscular atrophy: insights from a multicenter retrospective study"],"prefix":"10.1007","volume":"271","author":[{"given":"Ningning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nachuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinXue","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8011-0274","authenticated-orcid":false,"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"12567_CR1","doi-asserted-by":"crossref","first-page":"11939","DOI":"10.3390\/ijms241511939","volume":"24","author":"H Nishio","year":"2023","unstructured":"Nishio H, Niba ETE, Saito T et al (2023) Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci 24:11939","journal-title":"Int J Mol Sci"},{"key":"12567_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J (2020) Advances in treatment of spinal muscular atrophy\u2014new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 7:1\u201313","journal-title":"J Neuromuscul Dis"},{"key":"12567_CR3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L et al (2018) Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 28:208\u2013215","journal-title":"Neuromuscul Disord"},{"key":"12567_CR4","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.3390\/ijms22157896","volume":"22","author":"MER Butchbach","year":"2021","unstructured":"Butchbach MER (2021) Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implications for spinal muscular atrophy phenotype and therapeutics development. Int J Mol Sci 22:7896","journal-title":"Int J Mol Sci"},{"key":"12567_CR5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/archdischild-2021-323605","volume":"108","author":"VL Gowda","year":"2023","unstructured":"Gowda VL, Fernandez-Garcia MA, Jungbluth H et al (2023) New treatments in spinal muscular atrophy. Arch Dis Child 108:511\u2013517","journal-title":"Arch Dis Child"},{"key":"12567_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","volume":"39","author":"J Erdos","year":"2022","unstructured":"Erdos J, Wild C (2022) Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. Eur J Paediatr Neurol 39:1\u201310","journal-title":"Eur J Paediatr Neurol"},{"key":"12567_CR7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","volume":"63","author":"G Acsadi","year":"2021","unstructured":"Acsadi G, Crawford TO, M\u00fcller-Felber W et al (2021) Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study. Muscle Nerve 63:668\u2013677","journal-title":"Muscle Nerve"},{"key":"12567_CR8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R et al (2020) Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 19:317\u2013325","journal-title":"Lancet Neurol"},{"key":"12567_CR9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M et al (2018) Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur J Neurol 25:512\u2013518","journal-title":"Eur J Neurol"},{"key":"12567_CR10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/mus.27519","volume":"65","author":"N Rad","year":"2022","unstructured":"Rad N, Cai H, Weiss MD (2022) Management of spinal muscular atrophy in the adult population. Muscle Nerve 65:498\u2013507","journal-title":"Muscle Nerve"},{"key":"12567_CR11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","volume":"16","author":"E Bertini","year":"2017","unstructured":"Bertini E, Dessaud E, Mercuri E et al (2017) Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:513\u2013522","journal-title":"Lancet Neurol"},{"key":"12567_CR12","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST et al (2019) Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology 92:e2492\u2013e2506","journal-title":"Neurology"},{"key":"12567_CR13","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/acn3.51906","volume":"10","author":"KM Kelly","year":"2023","unstructured":"Kelly KM, Mizell J, Bigdeli L et al (2023) Differential impact on motor unit characteristics across severities of adult spinal muscular atrophy. Ann Clin Transl Neurol 10:2208\u20132222","journal-title":"Ann Clin Transl Neurol"},{"key":"12567_CR14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW et al (2017) Natural history of infantile-onset spinal muscular atrophy. Ann Neurol 82:883\u2013891","journal-title":"Ann Neurol"},{"key":"12567_CR15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","volume":"23","author":"WC Weng","year":"2021","unstructured":"Weng WC, Hsu YK, Chang FM et al (2021) CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening. Genet Med 23:415\u2013420","journal-title":"Genet Med"},{"key":"12567_CR16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732","journal-title":"N Engl J Med"},{"key":"12567_CR17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","volume":"6","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy SA, Kolb SJ, Lowes L et al (2019) AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J Neuromuscul Dis 6:307\u2013317","journal-title":"J Neuromuscul Dis"},{"key":"12567_CR18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13023-021-01771-y","volume":"16","author":"A Lusakowska","year":"2021","unstructured":"Lusakowska A, Jedrzejowska M, Kaminska A et al (2021) Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy. Orphanet J Rare Dis 16:150","journal-title":"Orphanet J Rare Dis"},{"key":"12567_CR19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1474-4422(20)30068-5","volume":"19","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Sansone V (2020) Nusinersen in adults with spinal muscular atrophy: new challenges. Lancet Neurol 19:283\u2013284","journal-title":"Lancet Neurol"},{"key":"12567_CR20","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, O\u2019Hagen JM, McDermott MP et al (2011) Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III. J Child Neurol 26:1499\u20131507","journal-title":"J Child Neurol"},{"key":"12567_CR21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.nmd.2011.02.014","volume":"21","author":"E Mazzone","year":"2011","unstructured":"Mazzone E, Bianco F, Martinelli D et al (2011) Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord 21:406\u2013412","journal-title":"Neuromuscul Disord"},{"key":"12567_CR22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","volume":"74","author":"J Montes","year":"2010","unstructured":"Montes J, McDermott MP, Martens WB et al (2010) Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74:833\u2013838","journal-title":"Neurology"},{"key":"12567_CR23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young S, Montes J, Kramer SS et al (2016) Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve 54:836\u2013842","journal-title":"Muscle Nerve"},{"key":"12567_CR24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mus.26419","volume":"59","author":"MC Pera","year":"2019","unstructured":"Pera MC, Coratti G, Mazzone ES et al (2019) Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve 59:426\u2013430","journal-title":"Muscle Nerve"},{"key":"12567_CR25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012140","volume":"5","author":"KJ Swoboda","year":"2010","unstructured":"Swoboda KJ, Scott CB, Crawford TO et al (2010) SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of l-carnitine and valproic acid in spinal muscular atrophy. PLoS ONE 5:e12140","journal-title":"PLoS ONE"},{"key":"12567_CR26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S et al (2020) Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 91:1166\u20131174","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12567_CR27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s13311-022-01200-3","volume":"19","author":"M Gavriilaki","year":"2022","unstructured":"Gavriilaki M, Moschou M, Papaliagkas V et al (2022) Nusinersen in adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neurotherapeutics 19:464\u2013475","journal-title":"Neurotherapeutics"},{"key":"12567_CR28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/brain\/awac252","volume":"146","author":"A Pechmann","year":"2023","unstructured":"Pechmann A, Behrens M, D\u00f6rnbrack K et al (2023) Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain 146:668\u2013677","journal-title":"Brain"},{"key":"12567_CR29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","volume":"18","author":"A \u0141usakowska","year":"2023","unstructured":"\u0141usakowska A, W\u00f3jcik A, Fr\u0105czek A et al (2023) Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience. Orphanet J Rare Dis 18:230","journal-title":"Orphanet J Rare Dis"},{"key":"12567_CR30","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s10072-023-06698-9","volume":"44","author":"D Arslan","year":"2023","unstructured":"Arslan D, Inan B, Kilinc M et al (2023) Nusinersen for adults with spinal muscular atrophy. Neurol Sci 44:2393\u20132400","journal-title":"Neurol Sci"},{"key":"12567_CR31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejpn.2021.02.007","volume":"31","author":"L Heitschmidt","year":"2021","unstructured":"Heitschmidt L, Pichlmaier L, Eckerland M et al (2021) Nusinersen does not improve lung function in a cohort of children with spinal muscular atrophy\u2014a single-center retrospective study. Eur J Paediatr Neurol 31:88\u201391","journal-title":"Eur J Paediatr Neurol"},{"key":"12567_CR32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","volume":"15","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Veldhoen ES, van Eijk RPA et al (2020) Natural history of lung function in spinal muscular atrophy. Orphanet J Rare Dis 15:88","journal-title":"Orphanet J Rare Dis"},{"key":"12567_CR33","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.3390\/pharmaceutics14102074","volume":"14","author":"M Axente","year":"2022","unstructured":"Axente M, Mirea A, Sporea C et al (2022) Clinical and electrophysiological changes in pediatric spinal muscular atrophy after 2 years of nusinersen treatment. Pharmaceutics 14:2074","journal-title":"Pharmaceutics"},{"key":"12567_CR34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.21838","volume":"42","author":"A Lewelt","year":"2010","unstructured":"Lewelt A, Krosschell KJ, Scott C et al (2010) Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 42:703\u2013708","journal-title":"Muscle Nerve"},{"key":"12567_CR35","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","volume":"17","author":"CA Chiriboga","year":"2017","unstructured":"Chiriboga CA (2017) Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother 17:955\u2013962","journal-title":"Expert Rev Neurother"},{"key":"12567_CR36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ et al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 29:842\u2013856","journal-title":"Neuromuscul Disord"},{"key":"12567_CR37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","volume":"92","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam D, D\u2019Silva A, Howells J et al (2020) Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry 92:78\u201385","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12567_CR38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/acn3.23","volume":"1","author":"WD Arnold","year":"2014","unstructured":"Arnold WD, Porensky PN, McGovern VL et al (2014) Electrophysiological biomarkers in spinal muscular atrophy: preclinical proof of concept. Ann Clin Transl Neurol 1:34\u201344","journal-title":"Ann Clin Transl Neurol"},{"key":"12567_CR39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti G, Cutrona C, Pera MC et al (2021) Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis 16:430","journal-title":"Orphanet J Rare Dis"},{"key":"12567_CR40","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","volume":"30","author":"G Coratti","year":"2020","unstructured":"Coratti G, Pera MC, Lucibello S et al (2020) Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul Disord 30:756\u2013764","journal-title":"Neuromuscul Disord"},{"key":"12567_CR41","volume":"13","author":"J Montes","year":"2018","unstructured":"Montes J, McDermott MP, Mirek E et al (2018) Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PLoS ONE 13:e0199657","journal-title":"PLoS ONE"},{"key":"12567_CR42","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/mus.23967","volume":"49","author":"PB Kang","year":"2014","unstructured":"Kang PB, Gooch CL, McDermott MP et al (2014) The motor neuron response to SMN1 deficiency in spinal muscular atrophy. Muscle Nerve 49:636\u2013644","journal-title":"Muscle Nerve"},{"key":"12567_CR43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625\u2013635","journal-title":"N Engl J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12567-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T12:22:26Z","timestamp":1725538946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12567-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["12567"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12567-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests related to the content of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed according to the Declaration of Helsinki and later amendments and approved by the Ethics Committee of Huashan Hospital Affiliated to Fudan University (approval number YN\/013\/2023).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}}]}}